Journals / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 3

Paricalcitol and Calcitriol Prevent Progression of Chronic Kidney Disease in Uremic Rats

Pages
194–201
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Paricalcitol and calcitriol therapy may prevent chronic kidney disease progression in uremic rats as they restore vitamin D metabolism during the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic kidney disease is common, irreversible, and associated with high mortality and morbidity.
📊
Key Findings & Data:Methods: Male Wistar-albino rats were fed a diet containing 0.75% adenine + 1.2% phosphorus for 3 weeks to induce chronic kidney disease.
💡
Conclusion & Impact:Conclusion: Paricalcitol and calcitriol therapy may prevent chronic kidney disease progression in uremic rats as they restore vitamin D metabolism during the disease.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Chronic kidney disease is common, irreversible, and associated with high mortality and morbidity. In this study, we aimed to investigate the effects of calcitriol and paricalcitol on chronic kidney disease progression in an adenineinduced uremic rat model. Methods: Male Wistar-albino rats were fed a diet containing 0.75% adenine + 1.2% phosphorus for 3 weeks to induce chronic kidney disease. The rats were randomly divided into 6 groups: control group (n = 12), chronic kidney disease group (n = 12), chronic kidney disease+ calcitriol group (n = 12), chronic kidney disease +paricalcitol group (n = 12), calcitriol group (n = 6), paricalcitol group (n = 6). Animals were monitored for weight and systolic blood pressure. The kidney function parameters, parathyroid hormone, monocyte chemoattractant protein-1, and kidney histology were investigated. This research was supported by the Scientific Research Projects Unit (11-TIP-062). Results: Kidney histology proved that the adenine-induced uremic rat model was successfully established. Serum urea, creatinine, and phosphorus were significantly higher in chronic kidney disease, chronic kidney disease + calcitriol, chronic kidney disease +paricalcitol groups compared with the control group (P < .05). Calcitriol and paricalcitol provide effective parathyroid hormone suppression and decrease serum monocyte chemoattractant protein-1 levels in uremic rats. All uremic rats, including the paricalcitol and calcitriol treatment groups, lost weight. Paricalcitol significantly lowered systolic blood pressure in uremic rats (P = .006). Serum calcium was higher in calcitriol group compared with chronic kidney disease group. Paricalcitol caused less hyperphosphatemia in non-uremic rats than calcitriol. Conclusion: Paricalcitol and calcitriol therapy may prevent chronic kidney disease progression in uremic rats as they restore vitamin D metabolism during the disease.

🔖

Cite This Article

ÖZDEMİR, Z. N., ŞEN, S., DUMAN, S., HUR, E., ACAR, A. G. (2022). Paricalcitol and Calcitriol Prevent Progression of Chronic Kidney Disease in Uremic Rats. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 3, 194–201. https://ajindex.com/articles/612802

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017
  2. 389(10075):1238-1252. [CrossRef] 2. Disease GBD, Injury I, Prevale C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018
  3. 392(10159):1789-1858. 3. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018
  4. 392(10159):2052-2090. [CrossRef] 4. Hu MC, Kuro-o M, Moe OW. Renal and extrarenal actions of klotho. Semin Nephrol. 2013
  5. 33(2):118-129. [CrossRef] 5. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004
  6. 19(3):429-435. [CrossRef] 6. Bosworth C, de Boer IH. Impaired vitamin D metabolism in CKD. Semin Nephrol. 2013
  7. 33(2):158-168. [CrossRef] 7. Dusso A, Lopez-Hilker S, Lewis-Finch J, et al. Metabolic clearance rate and production rate of calcitriol in uremia. Kidney Int. 1989
  8. 35(3):860-864. [CrossRef] 8. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Ren Physiol. 2005
  9. 289(1):F8-F28. [CrossRef] 9. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. 2005
  10. 98(10):1024-1027. [CrossRef] 10. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004
  11. 79(3):362-371. [CrossRef] 11. Schlereth F, Badenhoop K. Vitamin D: more than just a bone hormone. Internist (Berl). 2016
  12. 57(7):646-655. [CrossRef] 12. Yang HC, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models. 2010
  13. 7(1-2):13-19. [CrossRef] 13. Hodeify R, Megyesi J, Tarcsafalvi A, Mustafa HI, Hti Lar Seng NS, Price PM. Gender differences control the susceptibility to ER stress-induced acute kidney injury. Am J Physiol Ren Physiol. 2013
  14. 304(7):F875-F882. [CrossRef] 14. Diwan V, Small D, Kauter K, Gobe GC, Brown L. Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats. Am J Physiol Ren Physiol. 2014
  15. 307(11):F116 9-F1178. [CrossRef] 15. Diwan V, Mistry A, Gobe G, Brown L. Adenine-induced chronic kidney